Worksure Medpharma Consultancy India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.08 M
- Revenue Growth 38.46%
- Profit Growth 208.99%
- Ebitda 108.59%
- Net Worth 44.29%
- Total Assets 20.38%
About Worksure Medpharma Consultancy India
Worksure Medpharma Consultancy India Private Limited (WMCIPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 June 2010 and has a history of 14 years and seven months. Its registered office is in New Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.08 M.
Usha Pathak and Ankit Pathak serve as directors at the Company.
Company Details
-
Location
New Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85100DL2010PTC204324
-
Company No.
204324
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Jun 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Worksure Medpharma Consultancy India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Usha Pathak
|
Director | 19-Jun-2010 | Current |
|
Ankit Pathak
|
Director | 19-Jun-2010 | Current |
Financial Performance of Worksure Medpharma Consultancy India.
Worksure Medpharma Consultancy India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 38.46% increase. The company also saw a substantial improvement in profitability, with a 208.99% increase in profit. The company's net worth Soared by an impressive increase of 44.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Worksure Medpharma Consultancy India?
In 2020, Worksure Medpharma Consultancy India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Worksure Biologicals Private LimitedAnkit Pathak is a mutual person
Charges (Loans)
₹2.08 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Mar 2022 | Hdfc Bank Limited | ₹2.08 M | Open |
How Many Employees Work at Worksure Medpharma Consultancy India?
Unlock and access historical data on people associated with Worksure Medpharma Consultancy India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Worksure Medpharma Consultancy India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Worksure Medpharma Consultancy India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.